Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Animal Health, Inc. (Jaguar Health) on June 29, 2017. The filing discloses the entry into a Material Definitive Agreement involving a new financing arrangement and the creation of a direct financial obligation.
Key Financial Metrics and Transaction Details
The Company entered into a Securities Purchase Agreement with Chicago Venture Partners, L.P. (CVP) to issue a convertible promissory note with the following terms:
- Principal Amount: $2,155,000
- Purchase Price: $1,700,000
- Original Issue Discount (OID): $425,000
- Transaction Expenses Included: $30,000
- Interest Rate: 8% per annum
- Maturity Date: August 2, 2018
- Conversion Price: $1.00 per share (subject to adjustments)
- Conversion Timing: Available after six months from the purchase date or upon the effective date of the resale registration statement, whichever is earlier.
Use of Proceeds: The Company is contractually required to use $1,000,000 of the net proceeds to reduce outstanding obligations under its existing loan agreement with Hercules Capital, Inc. The remainder will be used for general corporate purposes.
Material Changes and Agreements
Beyond the issuance of the Note, the filing details several related agreements:
- Subordination Agreement: CVP subordinated its debt and security interests to those of Hercules Capital, Inc. Hercules granted CVP the right to purchase 100% of the Company's term loan debt, contingent on full payout to Hercules.
- Security Agreement: CVP received a security interest in substantially all of the Company's assets. This interest becomes effective upon CVP's purchase of the Hercules Loan or upon full repayment of that loan.
- Redemption Rights: CVP has the right to redeem up to $350,000 of the Note per month, starting from the earlier of the Resale S-1 Effective Date or the Purchase Price Date. Redemptions must be in cash if the Company's stock trades below $1.15 per share.
- Covenants: The Company must maintain its reporting status, keep its stock listed on an exchange, and file a registration statement for the Conversion Shares by August 31, 2017, with effectiveness required within 90 days.
Guidance, Risks, and Contingencies
The filing does not provide forward-looking financial guidance or management commentary regarding future revenue or earnings. However, it outlines specific risks and obligations:
- Liquidity and Debt Structure: The transaction increases the Company's debt load while simultaneously reducing the Hercules Loan balance. The subordination of the new debt to the Hercules Loan indicates a prioritization of existing senior debt.
- Conversion Restrictions: CVP is restricted from converting the Note if the resulting ownership would exceed 9.99% of the Company's total issued and outstanding common stock.
- Compliance Risks: Failure to comply with covenants, such as timely filing of reports or maintaining stock exchange listing, may result in liquidated damages.
- Registration Requirement: The Company faces a strict deadline to file and declare effective a resale registration statement for the conversion shares.
Investor Verification Checklist
- Verify the current outstanding balance of the Hercules Capital, Inc. loan to assess the impact of the $1,000,000 mandatory repayment.
- Confirm the status of the resale registration statement (S-1) required to be filed by August 31, 2017.
- Monitor the Company's stock price relative to the $1.15 threshold, which dictates whether CVP's monthly redemptions must be paid in cash.
- Review the Company's cash position to ensure it can service the 8% interest on the new Note and meet potential redemption requests.
- Check for any subsequent filings regarding the purchase of the Hercules Loan by CVP, which would trigger the Security Agreement.